These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34445019)

  • 41. An in vitro assay to measure targeted drug delivery to bone mineral.
    Jahnke W; Henry C
    ChemMedChem; 2010 May; 5(5):770-6. PubMed ID: 20209564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120).
    Rozenberg S; Lanoy E; Bentata M; Viard JP; Valantin MA; Missy P; Darasteanu I; Roux C; Kolta S; Costagliola D;
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):972-80. PubMed ID: 22353022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Clin Rheumatol; 2007 Feb; 26(2):161-7. PubMed ID: 16565894
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plant phosphates, phytate and pathological calcifications in chronic kidney disease.
    Buades Fuster JM; Sanchís Cortés P; Perelló Bestard J; Grases Freixedas F
    Nefrologia; 2017; 37(1):20-28. PubMed ID: 27697413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
    Hejdova M; Palicka V; Kucera Z; Vlcek J
    Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL; Hu B; Reed S; Mirocha J; Adams JS
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
    Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phytate inhibits bovine pericardium calcification in vitro.
    Grases F; Sanchis P; Costa-Bauzá A; Bonnin O; Isern B; Perelló J; Prieto RM
    Cardiovasc Pathol; 2008; 17(3):139-45. PubMed ID: 18402805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
    Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
    Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis.
    Nabhan AF; Rabie NH
    Int J Gynaecol Obstet; 2008 Dec; 103(3):213-6. PubMed ID: 18805524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
    Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
    J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.